GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » Cyclically Adjusted Price-to-FCF

Delcath Systems (FRA:DV3R) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Delcath Systems Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Delcath Systems's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Cyclically Adjusted Price-to-FCF Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Delcath Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Delcath Systems's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Delcath Systems's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Cyclically Adjusted Price-to-FCF falls into.



Delcath Systems Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Delcath Systems's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Delcath Systems's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.355/131.7762*131.7762
=-0.355

Current CPI (Mar. 2024) = 131.7762.

Delcath Systems Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 -1,518.000 104.136 -1,920.921
201712 -1,643.500 104.011 -2,082.222
201803 -5,230.000 105.290 -6,545.662
201806 -2,454.000 106.317 -3,041.653
201809 -61.118 106.507 -75.619
201812 -108.733 105.998 -135.176
201903 -23.362 107.251 -28.704
201906 -27.696 108.070 -33.772
201909 -110.029 108.329 -133.844
201912 -72.090 108.420 -87.620
202003 -67.055 108.902 -81.140
202006 -3.084 108.767 -3.736
202009 -1.036 109.815 -1.243
202012 -0.701 109.897 -0.841
202103 -0.592 111.754 -0.698
202106 -0.892 114.631 -1.025
202109 -0.556 115.734 -0.633
202112 -0.683 117.630 -0.765
202203 -0.717 121.301 -0.779
202206 -0.703 125.017 -0.741
202209 -0.575 125.227 -0.605
202212 -0.691 125.222 -0.727
202303 -0.343 127.348 -0.355
202306 -0.714 128.729 -0.731
202309 -0.481 129.860 -0.488
202312 -0.327 129.419 -0.333
202403 -0.355 131.776 -0.355

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Delcath Systems  (FRA:DV3R) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Delcath Systems Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines